Diabetes Treatment Report

www.DiabetesTreatmentReport.com

admin

Harnessing CD8(+) T-cell exhaustion to treat type 1 diabetes

https://pubmed.ncbi.nlm.nih.gov/33548057/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

TITLE:
Harnessing CD8(+) T-cell exhaustion to treat type 1 diabetes

DESCRIPTION:
Although immune interventions have shown great promise in type 1 diabetes mellitus (T1D) clinical trials, none are yet in routine clinical use or able to achieve insulin independence in patients. In addition to this, the principles of T1D treatment remain essentially unchanged since the isolation of insulin, almost a century ago. T1D is characterized by insulin deficiency as a result of destruction of insulin-producing beta cells mediated by autoreactive T cells. Therapies that target beta-cell…

PMID:
pubmed:33548057

DATE FOUND:
02/24/21 03:35AM

LINK / URL:
https://pubmed.ncbi.nlm.nih.gov/33548057/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

Phase 2, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

https://clinicaltrials.gov/ct2/show/NCT04509791?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F29%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

DESCRIPTION:
Condition:   Diabetes Mellitus, Type 1
Intervention:   Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Sponsor:   Universitaire Ziekenhuizen Leuven
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04509791

FIRST POSTED:
Wed, 12 Aug 2020 12:00:00 EDT

LAST UPDATE POSTED:
08/12/20 07:22AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04509791?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F29%2F2020&lupd_d=14&sort=nwst

Islet Transplant in Patients With Type I Diabetes

https://clinicaltrials.gov/ct2/show/NCT03698396?type=Intr

https://clinicaltrials.gov/ct2/show/NCT03698396?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F16%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Islet Transplant in Patients With Type I Diabetes

DESCRIPTION:
Condition:   Diabetes Mellitus, Type 1
Intervention:   Biological: Allogenic Islet Cell Transplantation
Sponsor:   Kenneth Brayman, MD
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03698396

FIRST POSTED:
Tue, 09 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
07/30/20 07:16AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03698396?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F16%2F2020&lupd_d=14&sort=nwst

Back to top